218 related articles for article (PubMed ID: 31929430)
1. CXCL9 Predicts Severity at the Onset of Chronic Graft-versus-host Disease.
Giesen N; Schwarzbich MA; Dischinger K; Becker N; Hummel M; Benner A; Radujkovic A; Müller-Tidow C; Dreger P; Luft T
Transplantation; 2020 Nov; 104(11):2354-2359. PubMed ID: 31929430
[TBL] [Abstract][Full Text] [Related]
2. Kynurenine pathway activation and deviation to anthranilic and kynurenic acid in fibrosing chronic graft-versus-host disease.
Orsatti L; Stiehl T; Dischinger K; Speziale R; Di Pasquale P; Monteagudo E; Müller-Tidow C; Radujkovic A; Dreger P; Luft T
Cell Rep Med; 2021 Oct; 2(10):100409. PubMed ID: 34755129
[TBL] [Abstract][Full Text] [Related]
3. Biomarker Panel for Chronic Graft-Versus-Host Disease.
Yu J; Storer BE; Kushekhar K; Abu Zaid M; Zhang Q; Gafken PR; Ogata Y; Martin PJ; Flowers ME; Hansen JA; Arora M; Cutler C; Jagasia M; Pidala J; Hamilton BK; Chen GL; Pusic I; Lee SJ; Paczesny S
J Clin Oncol; 2016 Aug; 34(22):2583-90. PubMed ID: 27217465
[TBL] [Abstract][Full Text] [Related]
4. EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis.
Luft T; Benner A; Jodele S; Dandoy CE; Storb R; Gooley T; Sandmaier BM; Becker N; Radujkovic A; Dreger P; Penack O
Lancet Haematol; 2017 Sep; 4(9):e414-e423. PubMed ID: 28733186
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after Allogeneic Hematopoietic Stem Cell Transplantation.
Inagaki J; Moritake H; Nishikawa T; Hyakuna N; Okada M; Suenobu S; Nagai K; Honda Y; Shimomura M; Fukano R; Noguchi M; Kurauchi K; Tanioka S; Okamura J
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1973-80. PubMed ID: 26234723
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms in CXCR3 ligands predict early CXCL9 recovery and severe chronic GVHD.
Dai H; Rachakonda SP; Penack O; Blau IW; Blau O; Radujkovic A; Müller-Tidow C; Dreger P; Kumar R; Luft T
Blood Cancer J; 2021 Feb; 11(2):42. PubMed ID: 33640906
[TBL] [Abstract][Full Text] [Related]
7. Risk-factor analysis for predicting progressive- or quiescent-type chronic graft-versus-host disease in a patient cohort with a history of acute graft-versus-host disease after allogeneic stem cell transplantation.
Sohn SK; Kim DH; Baek JH; Kim JG; Lee KB; Lee KH; Lee JH; Choi SJ; Lee JH; Shin IH
Bone Marrow Transplant; 2006 Apr; 37(7):699-708. PubMed ID: 16501588
[TBL] [Abstract][Full Text] [Related]
8. Plasma CXCL9 elevations correlate with chronic GVHD diagnosis.
Kitko CL; Levine JE; Storer BE; Chai X; Fox DA; Braun TM; Couriel DR; Martin PJ; Flowers ME; Hansen JA; Chang L; Conlon M; Fiema BJ; Morgan R; Pongtornpipat P; Lamiman K; Ferrara JL; Lee SJ; Paczesny S
Blood; 2014 Jan; 123(5):786-93. PubMed ID: 24363401
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation.
Pavletic SZ; Smith LM; Bishop MR; Lynch JC; Tarantolo SR; Vose JM; Bierman PJ; Hadi A; Armitage JO; Kessinger A
Am J Hematol; 2005 Apr; 78(4):265-74. PubMed ID: 15795914
[TBL] [Abstract][Full Text] [Related]
10. Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation-Results from a Single-Center Observational Study.
Grube M; Holler E; Weber D; Holler B; Herr W; Wolff D
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1781-1791. PubMed ID: 27343720
[TBL] [Abstract][Full Text] [Related]
11. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival.
Moon JH; Sohn SK; Lambie A; Ellis L; Hamad N; Uhm J; Gupta V; Lipton JH; Messner HA; Kuruvilla J; Kim D
Biol Blood Marrow Transplant; 2014 Apr; 20(4):556-63. PubMed ID: 24447907
[TBL] [Abstract][Full Text] [Related]
12. IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
Kattner AS; Holler E; Holler B; Klobuch S; Weber D; Martinovic D; Edinger M; Herr W; Wolff D
Ann Hematol; 2020 Apr; 99(4):847-853. PubMed ID: 32086584
[TBL] [Abstract][Full Text] [Related]
13. A survey of diagnosis, management, and grading of chronic GVHD.
Lee SJ; Vogelsang G; Gilman A; Weisdorf DJ; Pavletic S; Antin JH; Horowitz MM; Akpek G; Flowers ME; Couriel D; Martin PJ
Biol Blood Marrow Transplant; 2002; 8(1):32-9. PubMed ID: 11846354
[TBL] [Abstract][Full Text] [Related]
14. Response to immunosuppressive treatment predicts outcome in patients with chronic graft-versus-host disease: a single-center analysis of longitudinal data.
Crocchiolo R; Saillard C; Signori A; Fürst S; El Cheikh J; Castagna L; Oudin C; Granata A; Faucher C; Devillier R; Crocchiolo D; Sormani MP; Chabannon C; Blaise D
Biol Blood Marrow Transplant; 2013 Apr; 19(4):576-83. PubMed ID: 23270984
[TBL] [Abstract][Full Text] [Related]
15. Association between serum high-molecular-weight adiponectin level and the severity of chronic graft-versus-host disease in allogeneic stem cell transplantation recipients.
Nakasone H; Binh PN; Yamazaki R; Tanaka Y; Sakamoto K; Ashizawa M; Sato M; Terasako K; Kimura S; Kikuchi M; Kako S; Okuda S; Oshima K; Tanihara A; Nishida J; Abe Y; Kanda Y
Blood; 2011 Mar; 117(12):3469-72. PubMed ID: 21258011
[TBL] [Abstract][Full Text] [Related]
16. Occurrence and Severity of Donor Lymphocyte Infusion-Associated Chronic Graft-versus-Host Disease Influence the Clinical Outcomes in Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation.
Yu WJ; Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2019 May; 25(5):912-920. PubMed ID: 30485788
[TBL] [Abstract][Full Text] [Related]
17. National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen.
Saillard C; Crocchiolo R; Furst S; El-Cheikh J; Castagna L; Signori A; Oudin C; Faucher C; Lemarie C; Chabannon C; Granata A; Blaise D
Leuk Lymphoma; 2014 May; 55(5):1106-12. PubMed ID: 23822538
[TBL] [Abstract][Full Text] [Related]
18. Low Soluble Programmed Cell Death Protein 1 Levels After Allogeneic Stem Cell Transplantation Predict Moderate or Severe Chronic GvHD and Inferior Overall Survival.
Kordelas L; Buttkereit U; Heinemann FM; Horn PA; Giebel B; Beelen DW; Reinhardt HC; Rebmann V
Front Immunol; 2021; 12():694843. PubMed ID: 34630383
[TBL] [Abstract][Full Text] [Related]
19. [The clinical observation of serum specific biomarkers in patients with chronic graft-versus-host disease].
Chen T; Li XP; Zhang C; Kong PY; Gao QG; Tang L; Wang R; Yang SJ; Gao L; Liu Y; Gao L; Feng YM; Rao J; Peng XG; Zhang X
Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):948-952. PubMed ID: 31856446
[No Abstract] [Full Text] [Related]
20. Clinical significance of subcategory and severity of chronic graft-versus-host disease evaluated by National Institutes of Health consensus criteria.
Sato T; Ichinohe T; Kanda J; Yamashita K; Kondo T; Ishikawa T; Uchiyama T; Takaori-Kondo A
Int J Hematol; 2011 Apr; 93(4):532-541. PubMed ID: 21465116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
